logo

EVIDENCE • EXPERIENCE • OUTCOMES

INTELLIGENCE BYMDReviewer
Home
About
Peptides
Contact
Back
Pre-approval drug. This compound is in active clinical trials and is not yet FDA-approved. Information here is for situational awareness only and should not be used to inform prescribing decisions.
  • No Preview Available

eloralintide and tirzepatide

PipelinePhase 3PeptideInvestigationalNot approved yet. Being tested in human clinical trials.
Generic:
Eloralintide
Sponsor:
Eli Lilly and Company
Active US trials:
8
Earliest primary completion:
Mar 1, 2027
👋

No perspectives yet — be the first!

100% anonymous · Verified U.S. prescribers only

(no name, NPI, or practice ever shown)

On this page

  • Synopsis

Trials

  • Clinical trials
  • About this drug

Physicians

  • Physician Buzz
Similar Products
medicine
WEGOVY
medicine
FOUNDAYO
medicine
Contrave Extended-Release
medicine
Saxenda
Synopsis
Generated with AlphaAI
Product:
eloralintide and tirzepatide
Category:
Indication:
Mechanism:
Safety:
Dosing:
Patient:
Reviews:
No reviews yet
see more
Disclaimer: The synopsis and product information provided on Alpha.MD are derived from openFDA data and are for informational purposes only. This information may not be comprehensive, accurate, or up-to-date. Clinicians should exercise their own professional judgment in interpreting and using this information, and consult the official prescribing information for the most accurate and current details.

Clinical trials (8)

NCTPhaseStatusSponsorPrimary Completion
NCT07881458Phase 3RECRUITINGEli Lilly and CompanyOct 1, 2029
NCT07282600Phase 3RECRUITINGEli Lilly and CompanyJan 1, 2028
Status: Investigational
Tested in peopleEvidence: Tested in peopleTested in at least one proper controlled study in people, with results.
NCT07392190
Phase 3
RECRUITING
Eli Lilly and Company
Jun 1, 2028
NCT07353931Phase 3RECRUITINGEli Lilly and CompanyMar 1, 2028
NCT07321886Phase 3RECRUITINGEli Lilly and CompanyMar 1, 2028
NCT07589608Phase 2RECRUITINGEli Lilly and CompanySep 1, 2027
NCT07369011Phase 3RECRUITINGEli Lilly and CompanyMar 1, 2028
NCT07215559Phase 2ACTIVE_NOT_RECRUITINGEli Lilly and CompanyMar 1, 2027

About this drug

Status
Active in clinical trials
Last Refreshed
Nov 13, 2026

Physician Buzz

Pre-Approval Insights

Be the First to Share Your Perspective

Share your pre-launch perspective on eloralintide and tirzepatide and help peers make informed prescribing decisions.

Your 45-second perspective helps thousands of colleagues.

Help Peers Make Better Decisions

Your real-world insights guide colleagues

Anonymous to Pharmaceutical Companies

Your identity stays private — only specialty/region shown

See Peer Benchmarks

Compare your perspective to specialty peers

There isn't any reviews posted yet. You can be the first to review the product